Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders (2017 - 2026)

Takeda Pharmaceutical has reported Net Income towards Common Stockholders for 10 years, with the latest figure at $710.2 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 17.29% year-over-year to $710.2 million in Q2 2026; TTM through Jun 2026 was $574.3 million, a 76.16% decrease from a year earlier, with the FY2026 full-year figure at -$971.7 million, down 237.15% from the prior year.
• Net Income towards Common Stockholders was $710.2 million for Q2 2026 at Takeda Pharmaceutical, down from $792.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.0 billion in Q3 2023, with the low at -$2.4 billion in Q4 2025.
• Average Net Income towards Common Stockholders over 5 years is $548.8 million, with a median of $751.1 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders soared 912.2% in 2023, then slumped 422.64% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at $843.2 million in 2022, then sank by 75.05% to $210.4 million in 2023, then plunged by 422.64% to -$678.8 million in 2024, then slumped by 252.74% to -$2.4 billion in 2025, then surged by 129.66% to $710.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $710.2 million (Q2 2026), $792.0 million (Q1 2026), and -$2.4 billion (Q4 2025), per Business Quant data.